CNSP News & Events

CNS Pharmaceuticals has launched a new corporate growth strategy designed to build a high-value pipeline in neurology and oncology. The strategy is being led by the newly formed executive team with deep experience across neurology, oncology and rare disease drug development. The team is driving a disciplined, data-driven approach to identify, acquire and advance differentiated therapeutic programs capable of delivering meaningful clinical and commercial value. CNS Pharmaceuticals conducted an independent, rigorous evaluation of its existing pipeline, development priorities and broader market opportunities as part of a comprehensive strategic review. The process incorporated clinical probability-of-success modeling, competitive landscape assessments, regulatory pathway evaluations and risk-adjusted return analyses. The review was carried out in collaboration with external strategic advisors to ensure a disciplined, scientifically grounded and commercially focused path forward.Based on the outcome of this review, the Company is moving towards a defined strategic focus on acquiring or in-licensing preclinical and clinical-stage assets in the therapeutic areas of neurology and oncology. CNS Pharmaceuticals intends to prioritize programs with strong biological rationale, differentiated mechanisms of action, clearly defined development and regulatory pathways and compelling clinical and commercial potential. Particular emphasis will be placed on assets with defined value inflection points and those addressing areas of significant unmet medical need, positioning the Company's pipeline for long-term growth and value creation. Neurology and oncology remain two of the most active and rapidly advancing sectors in biotechnology, supported by large and growing global markets, significant scientific innovation and well-established regulatory frameworks that can accelerate development timelines. As part of the strategic review, CNS Pharmaceuticals also evaluated its legacy programs. While scientifically valuable, TPI 287 and berubicin do not align with the Company's forward-looking growth strategy. CNS Pharmaceuticals plans to prepare comprehensive partnering packages to explore potential out-licensing of these assets, enabling the Company to concentrate its resources on advancing a new acquisition-driven pipeline.

CNS Pharmaceuticals announced the appointment of Lynne Kelley, MD, FACS, as Chief Medical Officer. Prior to joining CNS Pharmaceuticals, Dr. Kelley served as CMO at multiple public and private biotechnology and medical device companies, including TISSIUM, Servier Pharmaceuticals, X4 Pharmaceuticals and Senseonics.

CNS Pharmaceuticals announced the Company's recently appointed President and CEO, Rami Levin, in close alignment with the Board of Directors, has recruited key members to his new executive team. These new appointments, which will be effective March 2, 2026, will help drive the Company's evolution. The Company announced the following appointments: Steven O'Loughlin as CFO; Eric Faulkner, MSc, MBA, as Chief Technology Officer; Dylan Wenke, MBA, as Chief Business Officer. Most recently, O'Loughlin served as CFO of Actinium Pharmaceuticals. Faulkner served in senior executive roles at IO Biotech, Homology Medicines, Shire and Biogen IDEC. Wenke held senior business development roles at Corbus Pharmaceuticals, Bluejay Therapeutics and EuMentis Therapeutics.